

**CRISPR/Cas9 Targets Chicken Embryonic Somatic Cells *In Vitro* and *In Vivo* and generates Phenotypic Abnormalities.**

Kwaku Dad Abu-Bonsrah<sup>1,2</sup>, Dongcheng Zhang<sup>1,2</sup> and Donald F. Newgreen<sup>2</sup>

<sup>1</sup>Department of Paediatrics, University of Melbourne, Parkville 3052, Australia

<sup>2</sup>Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, 3052, Australia

**Supplementary Table 1: Genes mutated or detected in this study**

Gene	Chicken c'some	Type, Function	Developmental expression/role	Human or rodent disease relationship	Present study
<i>CDKN1B</i>	1	Cyclin-dependent kinase inhibitor. Mediates G1 arrest.	Exp. ubiquitous. Leydig cell dev.	MEN4	NHEJ deletion DF-1 $\pm$ puromycin <i>in vitro</i> . Off-target screen DF-1, DT40 <i>in vitro</i> .
<i>CNN1</i> <i>Calponin1</i>	30	Neg reg by DROSHA.	Cytoskeletal -related	Severe atrioventricular septal defects	Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>DGCR8</i>	15micro	Complex & co-reg with DROSHA. miRNA processing.	Exp. wide esp. in neuroepithelium, palate, thymus, limbs.	DiGeorge critical region Het. reduced cell prolifer <sup>n</sup> and neurogenesis	Large transgenic deletion DF-1, DT40 <i>in vitro</i> . NHEJ deletion <i>in ovo</i> .
<i>DICER</i>	5	Ribonuclease III. miRNA processing.	Exp. ubiquitous esp. facial, pharyngeal arches and limb bud..	Up-reg. in melanoma Down-reg in breast carcinoma	NHEJ deletion DF-1 <i>in vitro</i> .
<i>DROSHA</i>	2	Ribonuclease III. miRNA processing. Complex & co-reg with <i>DGCR8</i>	Exp. ubiquitous esp. viscera.	Premature death Cachexia	NHEJ deletion DF-1 <i>in vitro</i> . Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>EZH2</i>	2	Polycomb family. Regulation DNA methylation. Histone modification.	Exp. neuroepithelium, pharyngeal arches, myotome, later esp. testis. Lung, CNS and B cell dev.	Weaver syndrome	NHEJ deletion DF-1 $\pm$ puromycin <i>in vitro</i> .
<i>HIRA</i>	15micro	Histone cell cycle regulator.	Exp. esp. pharyngeal arches.	DiGeorge critical region	NHEJ deletion DF-1 $\pm$ puromycin <i>in vitro</i> . Large transgenic deletion DF-1 <i>in vitro</i> .
<i>KIAA1279</i> <i>(KIF1BP)</i>	6	Regulation DNA methylation. Histone modification.	Exp. ubiquitous.	Goldberg-Shprintzen Hirschsprung	NHEJ deletion DF-1 $\pm$ puromycin <i>in vitro</i> . Off-target screen DF-1, DT40 <i>in vitro</i> . Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>NGN2</i>	4	Regulated by DROSHA/ <i>DGCR8</i> .	Exp. in neural tube, pharyngeal arches	PNET	Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>PAX6</i>	5	Paired box homeotic TF. Regulated by DROSHA / <i>DGCR8</i> .	Exp. in neural tube, pharyngeal arches, eye.	Aniridia	Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>MBD3</i>	28micro	NuRD complex subunit Chromatin alteration, epigenetic markers.	Exp. wide esp. in brain, pharyngeal arches, intestine	Siver-Russell syndrome	NHEJ deletion DF-1 $\pm$ puromycin <i>in vitro</i> . Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .

<i>RET</i>	6	GF receptor tyrosine kinase	Exp. in PNS, CNS, kidney. Survival, proliferat <sup>n</sup> , different <sup>n</sup> .	MEN2A, MEN2B, Hirschsprung	HDR gene editing C612R, M918T DF-1 <i>in vitro</i> . Large intragenic deletion DF-1 <i>in vitro</i> .
<i>STMN2</i>	2	Target of MAPK8 Regulation of microtubule stability	Exp. CNS and PNS. Neuronal growth.	Alzheimer	Large intragenic deletion DF-1, DT40 <i>in vitro</i> . NHEJ deletion <i>in ovo</i> . Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .
<i>TYRP1</i>	Z	Tyrosinase-related protein-1, melanosomal tyrosinase	Exp. epidermal NCC, retina. Melanin biosynthesis.	Rufous oculocutaneous albinism	NHEJ deletion DF-1 ±puromycin <i>in vitro</i> .
<i>YPEL1</i>	15micro	Centrosomal/nucleolar Regulated by DROSHA /DGCR8	Exp. in pharyngeal arches.	DiGeorge critical region	Exp. level after <i>DGCR8</i> NHEJ deletion <i>in ovo</i> .

Gene data from: <http://www.ncbi.nlm.nih.gov/gene/>

Expression data from:

<http://www.proteinatlas.org/search/>

[http://www.emouseatlas.org/emagewebapp/pages/emage\\_gene\\_browse.jsf](http://www.emouseatlas.org/emagewebapp/pages/emage_gene_browse.jsf)

Disease data from: <http://www.genecards.org/cgi-bin/carddisp.pl?gene=>

miRNA target data: <http://www.targetscan.org>

<http://www.microrna.org>

**Supplementary Table 2: Oligonucleotides for cloning sgRNA into CRISPR/Cas9 vector**

Gene or locus		Direction	Sequence 5' to 3'
<i>RET</i> exon 16	sgRNA #1	FP1	CCGGAGGGTCGGATACCTGTAAA
		RP1	AAACTTTAACAGGTATCCGACCCT
	sgRNA #2	FP2	CCGGTCTATGGCCATCCATTTAAC
		RP2	AAACGTAAATGGATGGCCATAGA
<i>RET</i> exon 10	sgRNA #1	FP1	CCGGTCACAATAACAGTTCTGTCT
		RP1	AAACAGACAGAACTGTTATTGTGA
<i>KIAA1279</i>	sgRNA #1	FP1	CCGGGCGGAACTTCTCGCACGCCG
		RP1	AAACCGGCGTGCGAGAAGTTCCGC
	sgRNA #2	FP2	CCGGCGGCGGCGACAAGATGGCGG
		RP2	AAACCCGCCATCTTGTCGCCGCCG
<i>MBD3</i>	sgRNA #1	FP1	CCGGGCACCTTTGACTTCCGCACG
		RP1	AAACCGTGCGGAAGTCAAAGGTGC
	sgRNA #2	FP2	CCGGGTCAAAGGTGCTCAGGTCCA
		RP2	AAACTGGACCTGAGCACCTTTGAC
<i>EZH2</i>	sgRNA #1	FP1	CCGGACACGTTTTCGCCAACAAAT
		RP1	AAACATTTGTTGGCGAAAACGTGT
	sgRNA #2	FP2	CCGGCTGAGAAAGGACCAATTTGT

		RP2	AAACACAAATTGGTCCTTTCTCAG
<i>CDKN1β</i>	sgRNA #1	FP1	CCGGCCCTACCCTGGAGCGCATGG
		RP1	AAACCCATGCGCTCCAGGGTAGGG
	sgRNA #2	FP2	CCGGCCGCGCCTCCATGCGCTCCA
		RP2	AAACTGGAGCGCATGGAGGCGCGG
<i>Stathmin-like 2 exon 1</i>	sgRNA #1	FP1	CCGGATTGCTGTTTTAGCCATGGT
		RP1	AAACACCATGGCTAAAACAGCAAT
	sgRNA #2	FP2	CCGG AGCGCCTGCACATCCCACCA
		RP2	AAACTGGTGGGATGTGCAGGCGCT
<i>Stathmin-like 2 exon 3</i>	sgRNA #1	FP1	CCGGTGAGGAGATCCAGAAAAAGC
		RP1	AAACGCTTTTTCTGGATCTCCTCA
	sgRNA #2	FP2	CCGGCGGCAGCCTCCAGCTTTTTTC
		RP2	AAACGAAAAAGCTGGAGGCTGCCG
<i>DGCR8 exon 2</i>	sgRNA #1	FP1	CCGGGTCTTCGTGCACCCAAAACA
		RP1	AAACTGTTTTGGGTGCACGAAGAC
	sgRNA #2	FP2	CCGGCACTTGTTTCTCCATCAGAC
		RP2	AAACGTCTGATGGAGAAACAAGTG
<i>HIRA</i>	sgRNA #1	FP1	CCGGTATGGCTCCTGTCCTGAAAAG
		RP1	AAACCTTTCAGGACAGGAGCCATA
<i>TYRP1</i>	sgRNA #1	FP1	CCGGACCATTGAGTCTCTGAGAAG
		RP1	AAACCTTCTCAGAGACTCAATGGT

**Supplementary Table 3: Primers for On-Target analysis.**

Gene or locus	Direction	Sequence 5' to 3'
<i>RET</i> exon 16	FP	AACAGATCATCTGTCAGCTTGTGT
	RP	TCCTCAGATTTAATTAATGGCA
<i>RET</i> exon 10	FP	CTACTCCAGTGCTCAGAAATCCAT
	RP	GTCTCCATGCACAAGTCAATATGC
<i>KIAA1279</i>	FP	GCCAGGGCCCTCGAGTAACCGCG
	RP	GCGCAGCCCCGCCCACCTGGGC
<i>MBD3</i>	FP	TGCACTTATTCTGCTAATTATGCTG
	RP	TGGACAGGCTTTGTTCTTGAGA
<i>EZH2</i>	FP	ATGGCCTGTTAATTTGTAATAAAAT
	RP	TTGATTCAATCACATACAAATGTA
<i>CDKN1B</i>	FP	TCGGCTGCTCCCCTCCGGAGCCG
	RP	GCCTGAAGTAGAAGTCGGGCGAG
<i>Stathmin</i> -like 2 exon 1	FP	GTGGATCAATATTTAATGCCCGGAG
	RP	TGATCTCAGATCGTTAAAAGAGCC
<i>Stathmin</i> -like 2 exon 3	FP	TAGTCTGTATTTCTGATCGTACACT
	RP	CAAGTTGCTGAAAGAAAATAAACT
<i>DGCR8</i> exon 2	FP	GGGATCATTGGACATTTCTAGTTC

	RP	ACAACAGATGAAGACAAAAAGCAC
<i>HIRA</i>	FP	TGTAAGTGTATCAGAATGGCCTCT
	RP	CCAGAGAAAGTTCACTGATTTCCA
<i>TYRP1</i>	FP	CTGGACTGGAGGTTTGTATTTCTT
	RP	CTAGGTGCATTAATAATCAACATGC

**Supplementary Table 4. Primers for Off-target Analysis and their Off-target sequence. Mismatch nucleotides are in red**


Gene or locus	Off-Target sequence	Direction	Sequence 5' to 3'
<i>RET</i> exon 16 OT	AGGGTCAGCCACCTGTAAAGGG	T7 FP	AGCACTCGAGTCAGGAGACTTAAT
		T7 RP	ATTGGAGGACTTCTTGTCTAGGTG
<i>RET</i> exon 10 OT1	TCAAATGACAGTTCTGTCTCAG	T7 FP	GAGAAACAGGAAAATAGGAACAGG
		T7 RP	CAGCTACTGTGACACTTGATTCAG
<i>RET</i> exon 10 OT2	CCATCATAACAGTTCTGTCTCAG	T7 FP	GACCTCAGCATAATCACATTGTTC
		T7 RP	TATCCTATGCTTTACACTCGTCCA
<i>KIAA1279</i> OT	GTGGAACTTCTCGCACGCAAGCGG	T7 FP	AAATAGGGGAGAAAAATGAGGAAG
		T7 RP	AATCCCGCTGGTAAAATATGTATG
<i>CDKN1β</i> OT	CAGCAACCTGGAGCGCATGGGAG	T7 FP	CAAGGCACAAAGTCTCATTGTTC
		T7 RP	CGTTGTCTTCATCCTTAGGTTTTT
<i>Stathmin</i> -like 2 exon 1 OT1	AGCTCCTGCACATCCCACCTGGG	T7 FP	TTTAAAAGGTAGTCCTGCTGCTCT
		T7 RP	GAGATTTTGCAGTTTCACAGAAGA
<i>Stathmin</i> -like 2 exon 1 OT2	ATCGCCACCACATCCCACCAAGG	T7 FP	TCCACGAAAGTATGCTGAGATAAA
		T7 RP	CTGGGAAAAGGATTACATTCAGAG
<i>Stathmin</i> -like 2 exon 3 OT	TTATAAGATTCAGAAAAAGCTGG	T7 FP	CACCCACAGTCAACTTATTTTTGT
		T7 RP	AAATGAGAGTTCCACAATGCAGTA

**Supplementary Table 5: Primers used in qPCR**


Gene or locus	Direction	Sequence 5' to 3'	Product size
<i>DROSHA</i>	FP	CATGGATCAAGTGGGGGACT	100 bp
	RP	GGCCTTTGCCTGTCGTTTTTC	
<i>NeuroG2</i>	FP	CACAACCTACATCTGGGCGCT	175 bp
	RP	GCGATAAAGTGCAGGCGTAG	
<i>DGCR8</i>	FP	GCATGAATATATGCAACGAGTCC	75 bp
	RP	GGCTCACTTGGGTTCTCACA	
ACTB	FP	GTATGTGCAAGGCCGGTTTC	92 bp
	RP	AACCATCACACCCTGATGTCT	
RPL32	FP	GTTACGACCCATCAGCCCTTG	93 bp
	RP	CATGATGCCGAGAAGGAGATGG	
<i>PAX6</i>	FP	GCGCAGTATAAACGAGAGTGC	187 bp
	RP	TCAGCATCCTTAGCTTGTCTGT	
<i>YPEL1</i>	FP	GAGCCCACCTAGCCAATCAC	132 bp
	RP	ACAGCCCACATTTACCACAG	
<i>STMN2</i>	FP	CGAGGAGAGGAGAAAAGTCCCA	150 bp
	RP	TGTTCCATTTTTCAGTATCAGCTTT	
<i>KIAA1279</i>	FP	CTACATCCAGGCCCAGAACA	141 bp
	RP	CTGGGATCCAGGGGAGGATT	

<i>MBD3</i>	FP	TCCAACCAAGCCAAAGGCAA	125 bp
	RP	GGATCACTCTTCACCTTATTGCTG	
<i>CNN1</i>	FP	ATAAGCTGGAGAACATTGGGAAC	97 bp
	RP	GTGTTCTCGAAGAGGTCGTTG	


S1A



B



C



**Supplementary Figure 1A.** Diagram of sgRNAs targeting sites on exon 10 (MEN2A/HSCR) and exon 16 (MEN2B) of the *RET* gene and the corresponding ssODN. Exons are shown in green boxes with location of sgRNA and sequences of PAM in red. Created (BamHI) and disrupted (EcoRV) restriction enzyme site are in purple. Desired base pair correction and its corresponding amino acid is represented in blue. (B) Frequency (%) of NHEJ mutations mediated by *Dicer* and *EZH2*-targeting sgRNA-Cas9 system in DF-1 cells with puromycin selection, by PCR and T7E1 assay. (C) Frequency (%) of NHEJ mutations mediated by *HIRA*, *TYRP1*, *EZH2*, *KIAA1279*, *CDKN1β*, and *Mbd3*-targeting sgRNA-Cas9 system in DF-1 cells with and without puromycin selection by PCR and T7E1 assay. Arrow indicates the NHEJ mutation created by the CRISPR/Cas9 system. 1kM-1 kbp DNA ladder. ND=not detected.

## S1D

### KIAA1279

GGCGGCGGCGACAAG <b>ATG</b> GCG GCG GCG GGT GGC GGG TGG GCC GCG GCG TGC GAG AAG TTC CGC AGC GCCAGGACGCTGCGGCCGTGGA	(wild type)	(x1)
M A A A G G G W A A A C E K F R S A R T L S A V		
GGCGGCGGCGACAAG <b>ATG</b> GCG GCG GCG GGT GGC GGG TGG GCC GCG G---TG CGA GAA GTT CCG CAG CGC CAGGACGCTGCGGCCGTGGA	(2bp deletion)	(x1)
M A A A G G G W A A V R E V P Q R Q D A V G R G	(frameshift)	
GGCGGCGGCGACAAG <b>ATG</b> GCG GCG GCG GGT GGC GGG TGG GCC GCG G---GT GCG AGA AGT TCC GCA GCG CCAAGGACGCTGCGGCCGTGGA	(1bp deletion)	(x2)
M A A A G G G W A A G A R S S A A P G R C R P W	(frameshift)	
GGCGGCGGCGACAAG <b>ATG</b> GCG GCG GCG GGT GGC GGG TG---C GAG AAG TTC CGC AGC GCCAGGACGCTGCGGCCGTGGA	(12bp deletion)	(x1)
M A A A G G G C E K F R S A R T L S A V	(frameshift)	
-----CGGCCGTGGA	(33bp deletion)	(x1)
R P W	(ORF disrupted)	
GGCGGCGGCGACAAG <b>ATG</b> GCG GCG GCG GGT GGC GGG TGG GCC GCG G---GA GAA GTT CCG CAG CGC CAGGACGCTGCGGCCGTGGA	(3bp deletion)	(x1)
M A A A G G G W A A G E V P Q R Q D A V G R G	(frameshift)	
GGCGGCGGCGACAAG-----TGC GAG AAG TTC CGC AGC GCCAGGACGCTGCGGCCGTGGA	(33bp deletion)	(x1)
C E K F R S A R T L S A V	(ORF disrupted)	

### CDKN1β



GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT ACC CTG GAG CGC ATG GAGGCGCGGCACTCGGAGTAC-	(wild type)	(x1)
M S N V R I S N G S P T L E R M E A R Q S E Y		
GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT ACC CTG GAG CGC <b>AT</b> GAGGCGCGGCACTCGGAGTAC	(1bp insertion)	(x1)
M S N V R I S N G S P T L E R N G G A A V G V	(frameshift)	
GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT ACC CTG G---AT GAGGCGCGGCACTCGGAGTAC	(3bp deletion)	(x1)
M S N V R I S N G S P T L D G G A A V G V	(frameshift)	
GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT ACC C---TG GAGGCGCGGCACTCGGAGTAC	(9bp deletion)	(x1)
M S N V R I S N G S P T L E A R Q S E Y	(frameshift)	
GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT <b>CC</b> CT---C---C---AT GAGGCGCGGCACTCGGAGTAC	(6bp deletion and 3bp insertion)	(x1)
M S N V R I S N G S P A L H G G A A V G V	(frameshift)	
GAGGGGGAG <b>ATG</b> TCA AAC GTC CGC ATT TCT AAT GGG AGC CCT ACC C---CG CAT GAGGCGCGGCACTCGGAGTAC	(3bp deletion)	(x1)
M S N V R I S N G S P T P H G G A A V G V	(frameshift)	

### MBD3

GCAGCAAAACCCAGCTGGCTCGCTACCTGGGCACTCC <b>ATG</b> GAC CTG AGC ACC TTT GAC TTC CGCACGGGAAAAATGCTGATGAGCAAA-	(wild type)	(x3)
M D L S T F D F R T G K M L M S K		
GCAGCAAAACCCAGCTGGCTCGCTACCTG-----AGC ACC TTT GAC TTC CGCACGGGAAAAATGCTGATGAGCAAA	(18bp insertion)	(x1)
M L M S K	(ORF disrupted)	
GCAGCAAAACCCAGCTGGCTCGCTACCTGGGCACTCCAT-----TGSACACCTTTGACTTCGACGGGAAAAATGCTGATGAGCAAA	(3bp deletion)	(x1)
M L M S K	(ORF disrupted)	
GCAGCAAAACCCAGCTGGCTCGCTACCTGGGCACTCC <b>ATG</b> GG---G CAC CTT TGACTTCCGACGGGAAAAATGCTGATGAGCAAA	(3bp deletion and 1bp insertion)	(x1)
M G H L stop	(ORF disrupted)	
GCAG-----GGAAAAATGCTGATGAGCAAA	(65bp deletion)	(x2)
M L M S K	(ORF disrupted)	
GCAGCAAAACCCAGCTGGCTCGCTACCTGGGCACTCCAT-----ACCTGAGCACCTTTGACTTCGACGGGAAAAATGCTGATGAGCAAA	(2bp deletion)	(x1)
M L M S K	(ORF disrupted)	
GCAGCAAAACCCAGCTGGCTCGCTACCTGGGCACT-----TTGACTTCCGACGGGAAAAATGCTGATGAGCAAA	(18bp deletion)	(x1)
M L M S K	(ORF disrupted)	

Supplementary Figure 1D. NHEJ mutations in *KIAA1279*, *CDKN1β* and *Mbd3* mediated by sgRNA-Cas9 in DF-1 cells. Red dashes and letters in red in the DNA sequences denote deleted nucleotides and inserted nucleotides respectively, and bold and underlined ATG indicates the translational initiation codon.






**D1** GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC AAA ACA **AGG** AGA GTA GAA AAT GAGAAATACGGTGGTGAAAGT wild type (x1)  
 D A L L E E G L R A P K T R R V E N  
 GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC ~~ACA~~ **AGG** AGA GTA GA A AAT GAGAAATACGGTGGTGAAAGT (3bp deletion) (x1)  
 D A L L E E G L R A P T R R V E N  
 GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC **AAA AAC AAG** GAG AGT AGA AAA IGA GAAATACGGTGGTGAAAGT(1bp insertion) (x1)  
 D A L L E E G L R A P K N K E S R K stop  
 GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC AAA **GGT GAG** GGA GAG TAG AAAATGAGAAATACGGTGGTG(3bp deletion/2bp insertions) (x1)  
 D A L L E E G L R A P K G E G E stop

**D2** GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC AAA ACA **AGG** AGA GTA GAA AAT GAGAAATACGGTGGTGAAAGT wild type (x7)  
 D A L L E E G L R A P K T R R V E N  
 GAT GCT CTG CTG GAA GAG GGT CTT CGT GCA CCC AA ~~G~~ GAG AGT AGA AAA IGA GAAATACGGTGGTGAAAGT (5bp deletion) (x2)  
 D A L L E E G L R A P K E S R K stop

**Supplementary Figure 2 (A)** A schematic representation of the *in ovo* electroporation technique and FACS. The mCherry CRISPR/Cas9 and the Tol2-GFP/transposase plasmids were co-injected or injected separately into the neural tube lumen (shaded green) of E1.5 chick embryos and electroporated. Embryos were harvested at stage E5.5, dissociated by collagenase/dispase and sorted by FACS or, alternatively, surrounding tissues were removed leaving the CNS for analysis. Representative images showing the extent of the electroporation and distribution of GFP-labelled cells was variable. **(B)** Frequency of NHEJ mutation mediated by exon 2 of DGCR8-targeting sgRNA-CRISPR/Cas9 system in chick embryo by PCR and T7E1 assay and sequence analysis of cloned DGCR8-1 (D8-1) and D8-2 sorted cells. Red dashes and letters in red in the DNA sequences denote deleted nucleotides and inserted nucleotides respectively, and bold indicates the PAM sequence with underlined nucleotide indicating the stop codon. mCherry<sup>low</sup> – mCherry low, mCherry<sup>high</sup> – mCherry high, mCherry<sup>ve</sup> -mCherry negative, 1M- 100 bp DNA ladder, ND=not detected.



S4A



**Supplementary Figure 4 (A)** Immunofluorescence images of single and merged channels of the indicated markers from frozen sections of postnatal mouse brain. **(B)** Validation of the Anti-DGCR8 antibody on chick embryonic brains and postnatal mouse brain by western blot, showing expected 87 and 117 kD bands. The previously observed band at 65 kD has not been identified by the supplier (Abcam).

S4B

